China+1 Strategy and the Paradox of Pharmaceutical Dependence

The global pharmaceutical landscape is undergoing a structural shift, often framed under the now-familiar “China+1 Strategy in a Fragmenting Global Order”—a response to geopolitical tensions, supply chain disruptions during the pandemic, and the growing realization that excessive concentration of manufacturing capacity in a single geography is a systemic risk. Historically, China’s rise as the “pharmacy of raw materials” was not accidental; it was built through decades of scale economics, state-backed industrial policy, environmental cost arbitrage, and deep integration into global value chains. By the early 2000s, India had already begun outsourcing bulk drug intermediates and Active Pharmaceutical Ingredients (APIs) to China, gradually hollowing out its domestic upstream manufacturing base while strengthening its position in finished generics.

However, the contemporary push for diversification has exposed a fundamental contradiction—“Strategic Diversification vs Structural Dependence”. While India is projected as a key beneficiary of the China+1 strategy, especially given its strong generics industry (supplying nearly 20% of global generics by volume), it continues to rely on China for nearly 60–70% of its API imports. This is not merely a trade statistic but a reflection of deeply embedded industrial asymmetries. The economics of API manufacturing—capital intensity, environmental compliance costs, scale efficiencies, and backward integration—continue to favor Chinese producers. Even where India has initiated Production Linked Incentive (PLI) schemes and bulk drug parks, the gestation period and cost competitiveness remain significant constraints.

The issue, therefore, is not just about shifting supply chains but addressing what can be termed as “The Illusion of Supply Chain Reconfiguration”. Diversification without rebuilding domestic capabilities risks becoming cosmetic. Global pharmaceutical firms may relocate formulation facilities or final-stage manufacturing to India, Vietnam, or Mexico, but the upstream chemical ecosystem often remains anchored in China. This creates a scenario where geopolitical risk is redistributed but not eliminated. In a crisis—whether geopolitical conflict, trade sanctions, or environmental shutdowns in China—India’s pharmaceutical exports could still face severe disruptions, undermining its reputation as a reliable global supplier.

From a historical perspective, this dependency can be traced back to policy choices made during the liberalization phase. India’s focus shifted toward cost-efficient generics production and export markets, while environmental regulations and cost pressures led to the closure or downsizing of many domestic bulk drug units. In contrast, China aggressively invested in chemical manufacturing clusters, supported by infrastructure, subsidies, and regulatory flexibility. Over time, this created a classic case of path dependency, where reversing the trend requires not just policy incentives but a systemic overhaul of industrial ecosystems.

Looking ahead, the challenge transforms into “From Cost Competitiveness to Strategic Resilience”. The future of the pharmaceutical industry will likely be shaped by a dual imperative—maintaining affordability while ensuring supply security. India’s policy response, including PLI schemes, bulk drug parks, and incentives for fermentation-based APIs, is a step in this direction, but scale and execution will determine outcomes. The real question is whether India can move beyond partial substitution toward full-spectrum integration—covering intermediates, key starting materials (KSMs), and advanced chemical synthesis.

A futuristic lens suggests that the next phase may not be about geographical diversification alone but about “Technological Disruption in API Manufacturing”. Advances in continuous manufacturing, green chemistry, synthetic biology, and AI-driven process optimization could redefine cost structures and reduce dependence on traditional large-scale chemical clusters. If India can align its digital and industrial strategies—leveraging its strengths in IT and pharmaceuticals—it could potentially leapfrog into a new paradigm of decentralized, high-efficiency production systems.

At the same time, the geopolitical dimension cannot be ignored. The China+1 strategy is as much about economics as it is about strategic alignment. Countries are increasingly viewing pharmaceuticals not just as a commercial sector but as a component of national security. This reframing introduces new variables—trade alliances, regulatory harmonization, and strategic stockpiling—which could reshape global supply chains in unpredictable ways. India, positioned at the intersection of Western markets and Asian manufacturing networks, has a unique opportunity but also a complex balancing act.

Ultimately, the evolving scenario can be captured as “The Future: Beyond China+1 to China+Many”. Rather than a binary shift away from China, the global system may evolve into a more distributed but still interdependent network, where China remains a dominant player while other countries build complementary capacities. For India, the real test will be whether it can transform from a formulation powerhouse into a fully integrated pharmaceutical ecosystem—one that combines scale, sustainability, and strategic autonomy.

The China+1 narrative, therefore, should not be mistaken for a solution in itself. It is merely an inflection point—a signal that the world is beginning to recognize the risks of over-concentration. The deeper transformation lies in rebuilding industrial depth, fostering innovation, and aligning policy with long-term strategic vision. Without this, dependence will persist, only in more complex and less visible forms.

#ChinaPlusOne

#APIdependence

#PharmaSupplyChain

#IndustrialPolicy

#StrategicAutonomy

#GlobalValueChains

#PLIIndia

#HealthcareSecurity

#ChinaIndiaTrade

#FutureOfPharma